{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T09:47:59Z","timestamp":1745488079758},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,16]]},"DOI":"10.7759\/cureus.10497","type":"journal-article","created":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T00:27:35Z","timestamp":1600302455000},"source":"Crossref","is-referenced-by-count":3,"title":["Achilles Tendon Xanthoma Thickness and Carotid Intima-Media Thickness in a Patient With Heterozygous Familial Hypercholesterolemia on PCSK9 Inhibition: A Case Report and Literature Review"],"prefix":"10.7759","author":[{"given":"Loba","family":"Alam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glenmore","family":"Lasam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Fishberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2008.10.032","article-title":"Regression of Achilles tendon thickness after statin treatment in patients with familial hypercholesterolemia: an ultrasonographic study","volume":"205","author":"Tsouli SG","year":"2009","unstructured":"Tsouli SG, Xydis V, Argyropoulou MI, Tselepis AD, Elisaf M, Kiortsis DN. Regression of Achilles tendon thickness after statin treatment in patients with familial hypercholesterolemia: an ultrasonographic study. Atherosclerosis. 2009, 205:151-155.  10.1016\/j.atherosclerosis.2008.10.032","journal-title":"Atherosclerosis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000183888.48105.d1","article-title":"The use of Achilles tendon sonography to distinguish familial hypercholesterolemia from other genetic dyslipidemias","volume":"25","author":"Junyent M","year":"2005","unstructured":"Junyent M, Gilabert R, Zamb\u00f3n D, et al.. The use of Achilles tendon sonography to distinguish familial hypercholesterolemia from other genetic dyslipidemias. Arterioscler Thromb Vasc Biol. 2005, 25:2203-2208.  10.1161\/01.ATV.0000183888.48105.d1","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2017-311213","article-title":"Imaging as a surrogate marker of drug efficacy in cardiovascular disease","volume":"105","author":"Tarkin JM","year":"2019","unstructured":"Tarkin JM, Dweck MR, Rudd JHF. Imaging as a surrogate marker of drug efficacy in cardiovascular disease. Heart. 2019, 105:567-578. 10.1136\/heartjnl-2017-311213","journal-title":"Heart"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2013.11.014","article-title":"Carotid intima-media thickness and plaque in cardiovascular risk assessment","volume":"7","author":"Naqvi TZ","year":"2014","unstructured":"Naqvi TZ, Lee MS. Carotid intima-media thickness and plaque in cardiovascular risk assessment. JACC Cardiovasc Imaging. 2014, 7:1025-1038. 10.1016\/j.jcmg.2013.11.014","journal-title":"JACC Cardiovasc Imaging"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.14740\/cr548w","article-title":"Heterozygous familial hypercholesterolemia with APOE haplotype: a prospective harbinger of a catastrophic cardiovascular event","volume":"8","author":"Lasam G","year":"2017","unstructured":"Lasam G, Shambhu S, Fishberg R. Heterozygous familial hypercholesterolemia with APOE haplotype: a prospective harbinger of a catastrophic cardiovascular event. Cardiol Res. 2017, 8:117-122. 10.14740\/cr548w","journal-title":"Cardiol Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.013225","article-title":"Diagnosis and treatment of heterozygous familial hypercholesterolemia","volume":"8","author":"McGowan MP","year":"2019","unstructured":"McGowan MP, Dehkordi SHH, Moriarty PM, Duell PB. Diagnosis and treatment of heterozygous familial hypercholesterolemia. J Am Heart Assoc. 2019, 8:e013225. 10.1161\/JAHA.119.013225","journal-title":"J Am Heart Assoc"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine MS","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, et al.. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017, 376:1713-1722.  10.1056\/NEJMoa1615664","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.P023994","article-title":"Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia","volume":"53","author":"Huijgen R","year":"2012","unstructured":"Huijgen R, Fouchier SW, Denoun M, Hutten BA, Vissers MN, Lambert G, Kastelein JJP. Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia. J Lipid Res. 2012, 53:979-983.  10.1194\/jlr.P023994","journal-title":"J Lipid Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial","volume":"316","author":"Nicholls SJ","year":"2016","unstructured":"Nicholls SJ, Puri R, Anderson T, et al.. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA. 2016, 316:2373-2384. 10.1001\/jama.2016.16951","journal-title":"JAMA"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx493.P6244","article-title":"Rapid carotid plaque reversal of PCSK9 inhibitors when added to statins and eicosapentaenoic acid in high risk cardiovascular patients","volume":"38","author":"Chan AQ","year":"2017","unstructured":"Chan AQ, Chal EL, Chan MP, Candic M, Antonio N, Wei D. Rapid carotid plaque reversal of PCSK9 inhibitors when added to statins and eicosapentaenoic acid in high risk cardiovascular patients. Eur Heart J. 2017, 38:1331. 10.1093\/eurheartj\/ehx493.P6244","journal-title":"Eur Heart J"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.628875","article-title":"Prediction of clinical cardiovascular events with carotid intima-media thickness","volume":"115","author":"Lorenz MW","year":"2007","unstructured":"Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness. Circulation. 2007, 115:459-467. 10.1161\/CIRCULATIONAHA.106.628875","journal-title":"Circulation"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/34469-achilles-tendon-xanthoma-thickness-and-carotid-intima-media-thickness-in-a-patient-with-heterozygous-familial-hypercholesterolemia-on-pcsk9-inhibition-a-case-report-and-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:22:48Z","timestamp":1707506568000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/34469-achilles-tendon-xanthoma-thickness-and-carotid-intima-media-thickness-in-a-patient-with-heterozygous-familial-hypercholesterolemia-on-pcsk9-inhibition-a-case-report-and-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,16]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.10497","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,16]]}}}